Cargando…
Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors
We previously conducted a phase-II study with selumetinib (AZD6244), a small molecule inhibitor of MEK1/2, in advanced biliary tract cancers (BTC), where the primary endpoint was response rate. Several patients experienced objective response. These findings were confirmed with MEK162 in a similar pa...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868687/ https://www.ncbi.nlm.nih.gov/pubmed/26683364 http://dx.doi.org/10.18632/oncotarget.6632 |